Question 1

Has tianeptine already been placed in Schedule I?

Accepted Answer

No. DEA published a proposed rule on July 8, 2026. Comments are open through August 7, 2026 at 11:59 p.m. ET, and DEA must review the record before deciding whether to issue a final rule with its own effective date.

Question 2

What exactly is DEA proposing?

Accepted Answer

DEA proposes Schedule I placement of tianeptine and its isomers, esters, ethers, and salts. If finalized, controls would reach possession, manufacture, distribution, import, export, research, and chemical analysis.

Question 3

What does Schedule I mean?

Accepted Answer

Schedule I is the most restrictive federal category, defined by high abuse potential, no currently accepted medical use in treatment in the United States, and lack of accepted safety under medical supervision.

Question 4

Why can't DEA place tianeptine in Schedule II, III, IV, or V instead?

Accepted Answer

Schedules II through V generally require a currently accepted U.S. medical use. Because tianeptine has no FDA-approved product, the framework pushes it toward Schedule I despite its prescription history abroad.

Question 5

Would the rule cover only products sold at gas stations?

Accepted Answer

No. The proposal controls the underlying substance and a broad range of chemical forms, not just retail products, so laboratory and research material would be covered as well.

Question 6

Is the campaign asking DEA to ignore tianeptine's risks?

Accepted Answer

No. High-dose tianeptine use has been associated with dependence, withdrawal, respiratory depression, overdose, and death. The question is whether permanent Schedule I control of the whole molecule is the proportionate response.

Question 7

Is tianeptine a real prescription medicine?

Accepted Answer

Tianeptine is not FDA-approved in the United States, but it has been marketed abroad as a prescription antidepressant for decades. That history is relevant evidence, though it does not by itself establish accepted U.S. medical use.

Question 8

Is tianeptine the same as heroin or fentanyl?

Accepted Answer

No. Tianeptine has mu-opioid receptor activity and real dependence potential at high doses, but it differs from heroin and fentanyl in potency, pharmacology, typical therapeutic exposure, and approved foreign use.

Question 9

Why does the dose matter?

Accepted Answer

The foreign therapeutic regimen described in the rule is 12.5 mg three times daily, while U.S. misuse reports involve hundreds to thousands of milligrams per day. Those exposures should not be evaluated as equivalent.

Question 10

Has tianeptine been studied for depression?

Accepted Answer

Yes. Tianeptine has been evaluated in antidepressant studies outside the United States and in a registered U.S. treatment-resistant depression study. That research does not equal FDA approval.

Question 11

Has tianeptine been studied for chronic pain?

Accepted Answer

There are preclinical and human research signals in fibromyalgia, post-mastectomy pain, and neuropathic pain models. None of this proves efficacy; it shows open research questions.

Question 12

What is the significance of the fibromyalgia trial?

Accepted Answer

A registered, completed, placebo-controlled fibromyalgia trial exists, but its results were not publicly reported, so it cannot be cited as proof of efficacy. It does show the hypothesis was considered plausible enough to test.

Question 13

How would Schedule I affect research?

Accepted Answer

Schedule I research remains legal with federal authorization, but it adds DEA registration, protocol, security, storage, and recordkeeping requirements that increase cost, delay, and administrative complexity.

Question 14

Why is the rule's treatment of isomers controversial?

Accepted Answer

The proposal covers tianeptine's isomers. Company-reported preliminary findings describe the S-isomer estianeptine as lacking mu-opioid activity, raising whether DEA has substance-specific evidence for every covered isomer.

Question 15

Who could be affected if the proposal is finalized?

Accepted Answer

People currently using tianeptine, people with physical dependence, clinicians, researchers, and laboratories could all be affected. HHS found more people sought tianeptine for perceived therapeutic purposes than for recreation.

Question 16

Would the proposed rule provide a transition or taper plan?

Accepted Answer

No. The proposal contains no clinical transition, tapering, or continuity-of-care program, even though prolonged high-dose use can produce opioid-like withdrawal.

Question 17

Could banning tianeptine push people toward more dangerous substances?

Accepted Answer

It is a plausible but not certain risk. Removing access without treatment or transition planning could lead some people back to illicit opioids, and DEA should evaluate that displacement risk.

Question 18

What was wrong with products such as Neptune's Fix?

Accepted Answer

A CDC investigation of severe illnesses linked to Neptune's Fix found variable compositions and undisclosed synthetic cannabinoid receptor agonists. CDC cautioned that severity may have reflected synthetic-cannabinoid toxicity, polysubstance exposure, or both.

Question 19

Aren't tianeptine products already illegal to sell in the United States?

Accepted Answer

FDA says tianeptine is not approved for any U.S. medical use and is not a lawful dietary ingredient. Schedule I would go further, adding controlled-substance consequences for possession, manufacture, distribution, import, and research.

Question 20

Would Schedule I create safer products?

Accepted Answer

Not by itself. Scheduling restricts who may handle a substance but does not create purity standards, accurate labeling, contaminant testing, or a supervised prescription system.

Question 21

How can I comment on the proposed rule?

Accepted Answer

Submit a comment through the official federal docket for Docket No. DEA1596 before 11:59 p.m. ET on August 7, 2026. State who you are, how the proposal affects you, your evidence, and the action you want DEA to take.

Question 22

What should I ask DEA to do?

Accepted Answer

A substantive comment may ask DEA to decline finalization, supplement the record, address omitted research, narrow the chemical scope, analyze covered isomers, preserve research access, or consider proportionate alternatives.

Question 23

Do public comments actually matter?

Accepted Answer

Yes, especially when they identify a specific factual omission, scientific limitation, legal issue, patient impact, or regulatory alternative that DEA can evaluate.

Question 24

Will my comment be public?

Accepted Answer

Generally yes. Comments become part of the public rulemaking record. This site does not submit comments; a submission is complete only when filed on the official docket and a Comment Tracking Number is received.

Tianeptine Schedule I: frequently asked questions

The Proposed Rule

Help Build the Public Record

Medicine and Science

Help Build the Public Record

Patients and Public Health

Help Build the Public Record

Taking Action

Help Build the Public Record